Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
BC Cancer Agency “Positioning for Excellence & Partnership with Industry” Dr. Samuel Abraham Vice-President Strategic Relationships & Vice-President Research BCCA – A Living Laboratory for Cancer Research Whitehorse, Yukon • Best outcomes in Canada - BC has the lowest age standardized mortality and incidence per 100,000 • Diverse population of ~ 4.61 million people • Province-wide screening programs • 13 networked tumour groups • A single population-based cancer control program Cancer Centre and Research Centre Centre Consultative Clinic Screening Mammography Centres, Cervical Cytology Screening Program Prince Rupert Terrace Kitimat Dawson Creek Prince George Kamloops Vernon Powell River Kelowna Penticton Nelson Campbell River Comox Port Alberni Nanaimo © Provincial Health Services Authority 2015 A centralized database of all Cranbrook cancer outcomes Chilliwack Trail Fraser Valley (Surrey) Vancouver Island Vancouver Abbotsford (Victoria) • Creston 2 Research at BCCA (FY 2015) • $270,316,062 in research funding in the past five years (does not include Clinical Trials) • 319 researchers - 120 of these are clinician/researchers • 519 trainees (masters, doctoral, post-doc fellows, practicum and co-op students) • 524 journal articles published, up 22% from the previous year 3 © Provincial Health Services Authority 2015 Partnerships • Academic partnerships – Affiliations with UBC, SFU, UVic, UNBC, CDRD, Genome BC – Inter-institutional Agreements with academic centers across the globe • Research Partnerships with Pharma and Biotech – Collaborative partnerships – Clinical Trials 4 © Provincial Health Services Authority 2015 Research Strategies • People – to attract, train and retain top caliber research personnel • Platforms – to leverage and strengthen the platforms in place and advance them to next-generation for the enhancement and sustainability of the research enterprise • Programs – to draw on the BCCA tumor site specific programs and population-based system to extract critical data for research & to translate new ideas and technologies into practice via the test-bed of a living laboratory at the BCCA • Partnerships – to create appropriate internal and external partnerships to drive the research mandate 5 © Provincial Health Services Authority 2015 Integration of BCCA Research Pipeline for Drug Discovery Genes Identification of Targets Validation of Targets Screening against compound libraries Pre Clinical Testing Clinical Testing BCCA has research platforms to move technologies from the lab to the clinic Patient Genome Sciences (Lymphoma, POG, Centre (GSC) Breast, etc) Programs Bioinformatics 6 © Provincial Health Services Authority 2015 Centre for Investigational Drug Research Drug & Development Program Clinical Trials Facility Functional Imaging Research Platforms Bioinformatics Platform - GSC; Molecular Oncology; Terry Fox Laboratory Clinical Trials Platform – across all BCCA sites Drug Development Platform- Investigational Drug Program (IDP) Functional Imaging – PET, Radiopharmaceutical Development Genomics Platform - Genome Analysis Platform at GSC Health Economics - Canadian Centre for Applied Research in Cancer Control (ARCC) Materials, Data and Tissue Platforms - Tumour Tissue Repository (TTR); BC Generations Project; Centre for Lymphoid Cancer; Genetic Pathology Evaluation Centre (GPEC); Epidemiology Permission to Contact Platform - Personal Response Determinants in Cancer Therapy (PREDICT) Personalized OncoGenomics Program – GSC, clinic Proteomics Platform - GSC 7 © Provincial Health Services Authority 2015 Clinical Trials Platform • BCCA has been performing clinical trials for over 30 years • Clinical trial capabilities available at all six cancer centres • High rates of enrollment: 9% of patients enroll in studies (Vancouver site) • Consistent enrollment (~300 patients in ~40 new trials per year) • Longitudinal follow-up of patients • Internationally renowned clinical researchers across multiple tumour groups • Close collaboration with researchers 8 © Provincial Health Services Authority 2015 8 Investigational Drug Program (IDP) BCCA operates a Drug Research Institute in partnership with the Centre for Drug Research and Development (CDRD) • Dr Marcel Bally (Head of Experimental Therapeutics at BCCA) is also CDRD Pharmacology and Toxicology Division Chair • IDP contributes to CDRD studies • Includes operational space (office and lab) and support of optical imaging IDP provides drug manufacturing products & services: • cGMP to fabricate and test in injectable format • cGLP compliant rodent safety testing (SCC accredited) • Analytical testing including stability studies • QA & QC monitoring • Clinical Trial Protocol Assistance and Support Services • Pre-Clinical Drug Evaluation Services 9 © Provincial Health Services Authority 2015 9 Genome Sciences Centre (GSC): A National Platform Clinical Genomics Dr Marco Marra (Director) • Since 2001, 593 projects totalling $772M with 25% international funding • 13 Illumina HiSeq 2500 sequencers • 10,000 cores, 8+ petabytes storage • GSC #5 in list of 10 best research facilities in Canada (Backbone Magazine, March 2013) • In silico drug development efforts led by Dr Steve Jones with a focus on chromatin remodeling • Cell survival/autophagy research led by Dr Sharon Gorski 10 © Provincial Health Services Authority 2015 10 BCCA Tumour Tissue Repository (Materials Platform) • Dr Peter Watson (Director) • Tissue Processing and Storage Laboratory: – state-of the-art : high resolution imaging system+ LaserAssisted Micro-dissection system • Bioinformatics Clinical Research Database: – IBM partnership – convergence of patient lifestyle, tumour and molecular data Advantages for validating cancer biomarkers: 11 • comprehensive patient and molecular data collection: precise tumour characterization and individualized patient therapy • A core component of the Canadian National Tumour Bank Network © Provincial Health Services Authority 2015 11 Personalized OncoGenomics Program Project Leaders Dr Janessa Laskin, Dr Marco Marra • A clinical research initiative • embeds genomic sequencing into real-time treatment planning for BC patients with incurable cancers • A research study for cancer patients with metastatic disease currently on first line treatment at the BC Cancer Agency • Outcome data available for 78 patients • results clinically informative in 65 cases (85%) • 55 cases (70%) actionable • 34 cases received treatment based on analysis • 14 cases experienced clinical benefit 12 © Provincial Health Services Authority 2015 12 Commercialization Metrics (FY 2011-2015) FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 Invention Disclosures 36 44 45 41 48 Patent Applications 22 22 17 16 27 41 45 47 56 61 18 24 28 32 36 7 7 7 7 6 (Provisional) Patents Issued (Cumulative since 2000) Active License Agreements (Cumulative since 2000) Active Spin off Companies (Cumulative since 2000) 13 © Provincial Health Services Authority 2015 Research Impacts Top 10 Listings in Canada (June 2013) • Patent applications per $M of research income: – Institutions on average applied for 0.12 patents per $1M of research funding – BCCA applied for 0.38 patents per $1M of research funding (Ranked #1) • Patents issued per $M of research income: – BCCA received 0.14 patents per $M of research funding (Ranked #1) • Patent applications submitted: – Top health organization - BCCA- applied for 22 patents 14 © Provincial Health Services Authority 2015 Spin Off Companies • • • • • • Coastal Genomics Verisante Technology Essa Pharmaceuticals Aquinox Pharmaceuticals Tekmira Pharmaceuticals Corp LED Medical Inc. 15 © Provincial Health Services Authority 2015 15 Coastal Genomics • Offers automation for Next Generation Sequencing for agarose gel loading, size selection, and sample extraction. • Ranger is only instrument to offer turnkey automation for agarose gel loading, size selection, and sample extraction. • Developed by Robin Coope at Genome Sciences Center • Vancouver based company • Start up: 2012 • Product placed at Beta sites 16 © Provincial Health Services Authority 2015 Verisante Technology • • • • • • • Commercial systems for the early detection of cancer Focus on skin cancer diagnosis using Raman spectroscopy Future products for GI, lung and cervix Technology developed by Dr Haishan Zeng in Medical Imaging Dept Vancouver based company Start up: 2010 Approved for sale in Canada, EU, and Australia 17 © Provincial Health Services Authority 2015 Essa Pharmaceuticals • Developing drugs to treat recurrent prostate cancer patients • Developing drugs which selectively block the N-terminus of the androgen receptor, by-passing mechanisms of Castrate-Resistant Prostate Cancer • Technology developed by Drs Marianne Sadar and Ray Anderson • Vancouver based company • Start up: 2009 • Pre-clinical development 18 © Provincial Health Services Authority 2015 Aquinox Pharmaceuticals • Novel and targeted small molecule therapeutics for the treatment of inflammatory disease and cancer • Target discovered by Dr Gerry Krystal • Vancouver based company • Start up: 2005 • Two Phase II trials completed 2013 • Other Phase II studies ongoing • US $98 Million financing 2015 19 © Provincial Health Services Authority 2015 Arbutus Biopharma • Marqibo (vincristine sulfate LIPOSOME injection) • For treatment of Acute Lymphoblastic Leukemia (ALL) in patients that test negative for the Philadelphia Chromosome (Ph-) • ALL is a dangerous and rare type of cancer – affects 4,000 new patients a year – two thirds of the cases in younger children – Due to the rarity of the disease, Marquibo has been granted orphan drug status • Marquibo is on the market as of September 2013 • Initial development by Dr Marcel Bally and colleagues at BCCA • Arbutus Biopharma is a Vancouver based company • Start up: 1999 (as Tekmira/Inex Pharma) 20 © Provincial Health Services Authority 2015 LED Medical Inc. • A leading developer of LED-based visualization technologies for the medical industry • Velscope assists in the discovery of oral abnormalities • Co-developed by Peter Whitehead and the Cancer Imaging Dept (now Integrative Oncology) • Vancouver based company started in 1997 • The VELscope Vx product released for sale 2013 21 © Provincial Health Services Authority 2015 Conclusion Unique linkage between clinic and researchers is impacting the care of cancer patients throughout the province Deploying research discoveries into the marketplace and promoting partnerships with industry is producing economic benefits and creating employment and investment in British Columbia through development of a strong technology sector 22 © Provincial Health Services Authority 2015 Thank you © Provincial Health Services Authority 2015